<DOC>
	<DOCNO>NCT01230697</DOCNO>
	<brief_summary>The study include recruitment patient advance renal cell carcinoma hepatocarcinoma treatment sorafenib . Multicenter cohort study . It prospective observational study .</brief_summary>
	<brief_title>Perspective Evaluation Hormones Involved Serum Phosphate Homeostasis Patients With Metastatic Renal Cells Carcinoma Hepatocellular Carcinoma Treated With Sorafenib ( SORHORM )</brief_title>
	<detailed_description>Several tyrosin kinase inhibitor able induce hypophosphatemia mechanism underling metabolic disorder unknown . Sorafenib probably drug metabolic disturbance frequent . The aim study identify variation blood serum analites involve hypophosphatemia patient advance renal cell carcinoma hepatocarcinoma treatment sorafenib .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1. age 18 year 2 . Histologically documented kidney cancer hepatocarcinoma 3 . Performance status / equal 2 4 . Life expectancy &gt; 12 week 5. patient recent surgery , wound completely heal take Sorafenib 6. require initial laboratory value : absolute neutrophil count &gt; 1500/ul Platelets &gt; 100,000/ul. , Hemoglobin &gt; 9.0 g/dl , Creatinine , SGOT , SGPT le 2.0 X upper limit normal Bilirubin le than/equal upper limit normal ( ULN ) 7 . Appropriate patienty compliance 1. myocardial infarction significant change anginal pattern within last 6 month , symptomatic congestive heart failure ( NYHA Class III high ) uncontrolled cardiac arrhythmia , 2. previous history malignant disease exception non melanoma skin cancer curatively treat , 3. significant neurologic psychiatric disease prevent patient give valid inform consent 4 . Sintomatic brain metastasis 5. patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude 6. patient seizure need medical treatment 7 . History heterologous transplantation 8 . Patients previous active bleeding 9 . Dialysis patient 10 . Patients history primary hyperparathyroidism 11 . Dysphagic patient 12 . Taking four week entry study biochemotherapy treatment 13 . Previous treatment Sorafenib 14 . Recent ( &lt; 6 month ) concomitant treatment biphosphonate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Advanced</keyword>
	<keyword>hepatocarcinoma</keyword>
</DOC>